Seeking Alpha

Fitch maintains Bristol-Myers Squibb's (BMY) debt rating at A+ and its outlook at Negative...

Fitch maintains Bristol-Myers Squibb's (BMY) debt rating at A+ and its outlook at Negative following the drug company's deal to buy Inhibitex (INHX) for $2.5B. While Bristol has enough cash to pay for Inhibitex, the latter won't provide immediate relief to an expected fall in Bristol's revenues because of the expiration of patents.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector